Apollo Endosurgery, Inc.·4/A

Aug 20, 8:55 PM ET

McKhann Chas 4/A

4/A · Apollo Endosurgery, Inc. · Filed Aug 20, 2021

Insider Transaction Report

Form 4/AAmended
Period: 2021-08-18
McKhann Chas
DirectorPresident and CEO
Transactions
  • Sale

    Common Stock

    2021-08-18$8.21/sh21,156$173,691686,122 total
  • Sale

    Common Stock

    2021-08-19$7.89/sh21,148$166,858664,974 total
  • Sale

    Common Stock

    2021-08-20$7.74/sh21,148$163,686643,826 total
Footnotes (4)
  • [F1]On March 10, 2021, the holder was granted 707,278 performance-based restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 12, 2021. One-quarter (25%) of these RSUs vested upon the Company's achievement of at least $50 million of revenue for the trailing four quarters ended June 30, 2021. Amounts reported represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs.
  • [F2]Represents weighted average price of shares sold. Prices ranged between $8.02 - $8.55, inclusive. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]Represents weighted average price of shares sold. Prices ranged between $7.68 - $8.15, inclusive. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]Represents weighted average price of shares sold. Prices ranged between $7.59 - $8.09, inclusive. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Documents

1 file
  • 4
    wf-form4a_162950729073044.xml

    FORM 4/A